Search | Haematologica

B04 | BLOOD-BASED RISK STRATIFICATION OF MYELOMA PATIENTS USING CIRCULATING TUMOR CELLS: RESULTS FROM THE EUROPEAN CTC CONSORTIUM (364 Online Views)

L. Bertamini¹, D. Zihala², I.V. Kostopoulos³, M. D’Agostino⁴, E. Martín-Sánchez⁵, J.J. Garcés Latre⁵, D. Hofste Op Bruinink¹, N. Puig⁶, S. Zweegman⁷, G. Bertuglia⁴, P. Malandrakis⁸, T. Sevcikova², T. Cupedo¹, N.W.C.J. Van De Donk⁷, M.T. Cedena⁹, P. Musto¹⁰, I. Ntanasis-Stathopoulos⁸, O. Venglar², M. Van Duin¹, J.J. Lahuerta⁹, D. Rota Scalabrini¹¹, O. Tsitsilonis³, T. Popkova², J. Blade¹², E. Zamagni¹³, M. Gavriatopoulou⁸, L. Muronova², B. Van Der Holt^1|14, P.. Moreau¹⁵, M.V. Mateos⁶, M. Galli¹⁶, E. Katodritou¹⁷, M. Stork¹⁸, A. Belotti¹⁹, P. Rousakis³, M. Borsky¹⁸, J. Corre²⁰, M. Boccadoro²¹, M. Dimopoulos⁸, R. Hajek², J. San Miguel⁵, P. Sonneveld¹, F. Gay⁴, E. Terpos⁸, A. Broijl¹, B. Paiva³, T. Jelinek²

¹ Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

² Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Czech Republic

³ Department of Biology, School of Science, National and Kapodistrian University of Athens, Greece

⁴ Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Italy

⁵ Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain

⁶ Hospital Universitario,Salamanca, Spain

⁷ Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, the Netherlands

⁸ Department of Clinical Therapeutics School of Medicine, National and Kapodistrian University of Athens, Greece

⁹ Hospital Universitario 12 De Octubre, Madrid, Spain

¹⁰ Department of Precision and Regenerative Medicine and Ionian Area,"Aldo Moro" University School of Medicine, and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy

¹¹ Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Torino, Italy

¹² Hospital Clínic de Barcelona, Spain

¹³ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Italy

¹⁴ HOVON Foundation, Rotterdam, the Netherlands

¹⁵ Hematology Department, University Hospital Hôtel-Dieu, Nantes, France

¹⁶ Hematology and Bone Marrow Transplant Unit, Azienda Socio-Sanitaria Territoriale-Papa Giovanni XXIII, Bergamo, Italy

¹⁷ Department of Hematology, Theageneio Cancer Hospital, Thessaloniki, Greece

¹⁸ Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic

¹⁹ Department of Hematology, ASST Spedali Civili di Brescia, Italy

²⁰ Unité de Génomique du Myélome, University Hospital, IUCT-Oncopole, CRCT, Toulouse, France

²¹ European Myeloma Network, EMN

Circulating Tumor Cells Multiple Myeloma Plasma Cell Egression.

P01 | CIRCULATING TUMOR CELLS IMPROVE RISK STRATIFICATION ACCORDING TO THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM AND THE IMS-IMWG CONSENSUS GENOMIC STAGING IN NDMM PATIENTS. AN ANALYSIS FROM THE EUROPEAN CTC CONSORTIUM (326 Online Views)

M. D’Agostino¹, E. Martín-Sánchez², D. Žihala^3|4, I. Kostopoulos⁵, J.J. Garcés⁶, N. Puig⁷, G. Bertuglia¹, T. Ševčíková³, T. Cupedo⁸, M. Van Duin⁸, J. Keats⁹, E. Zamagni^10|11, P. Moreau¹², S. Zweegman¹³, B. Van Der Holt^8|14, D. Hofste Op Bruinink⁸, E. Dama¹⁵, J. Corre¹⁶, M. Boccadoro¹⁵, M.A. Dimopoulos^17|18, R. Hájek^3|4, B. Paiva², P. Sonneveld^8|19, A. Broijl⁸, E. Terpos¹⁷, T. Jelínek^3|4, J. San-Miguel², F. Gay¹, L. Bertamini⁸

¹ Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Italy

² Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain

³ Department of Hematooncology, University Hospital Ostrava, Czech Republic

⁴ Department of Hematooncology, Faculty of Medicine, University of Ostrava, Czech Republic

⁵ School of Science, National and Kapodistrian University of Athens, Greece

⁶ Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, USA

⁷ Hospital Universitario Salamanca, Spain

⁸ Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

⁹ Clinical Genomics and Therapeutics Division, Translational Genomics Research Institute, Phoenix, USA

¹⁰ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Italy

¹¹ Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy

¹² Hematology Department, University Hospital Hôtel-Dieu, Nantes, France

¹³ Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit, The Netherlands

¹⁴ HOVON Foundation, Rotterdam, The Netherlands

¹⁵ European Myeloma Network, Italy

¹⁶ Unité de Génomique du Myélome, University Hospital, IUCT-Oncopole, CRCT, Toulouse, France

¹⁷ Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece

¹⁸ Department of Medicine, Korea University, Seoul, Korea

¹⁹ European Myeloma Network, The Netherlands

Circulating Tumor Plasma Cells NDMM European CTC Consortium.

P16 | INTEGRATED p53 ISOFORM EXPRESSION DEFINES NOVEL PROGNOSTIC SUBGROUPS IN MULTIPLE MYELOMA (274 Online Views)

E. Borsi¹, A. Vitale², V. Solli², V. Meixian Vuong², M. Martello¹, I. Vigliotta¹, S. Armuzzi², A. Poletti², B. Taurisano², A. Varacalli^1|2, G. Mazzocchetti², A. Croce², I. Pistis¹, E. Zamagni^2|1, P. Tacchetti¹, I. Rizzello^1|2, M. Cavo², C. Terragna¹

¹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy

² DIMEC – Dipartimento di Medicina e Chirurgia, Università di Bologna, Italy

p53 isoform Multiple Myeloma Prognostic Factors

P18 | MONOCLONAL AND POLYCLONAL CIRCULATING PLASMA CELLS ARE ASSOCIATED WITH DISEASE DISSEMINATION IN MULTIPLE MYELOMA (295 Online Views)

I. Vigliotta¹, A. Varacalli¹, M. Talarico^1|2, V. Solli², B. Taurisano², S. Armuzzi², I. Pistis¹, V.M. Vuong², A. Vitale¹, G. Mazzocchetti^3|4, E. Borsi¹, A. Croce², M. Martello¹, A. Poletti², C. Nanni⁵, K. Mancuso^1|2, M. Puppi^1|2, M. Cavo², E. Zamagni^1|2, C. Terragna¹

¹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy

² Department of Medical and Surgical Sciences - University of Bologna, Italy

³ FABIT-Department of Pharmacy and Biotechnology, University of Bologna, Italy

⁴ Computational and Chemical Biology, Italian Institute of Technology, CMP3VdA, Aosta, Italy

⁵ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Nuclear Medicine, Bologna, Italy

Circulating Plasma Cells Multiple Myeloma NDMM

P36 | EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER CILTACABTAGENE AUTOLEUCEL: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (393 Online Views)

E. Zamagni¹, B. Dhakal², S. Iida³, M.H. Sidiqi^4|5, S.S. Yoon⁶, N. Callander⁷, C. Touzeau^8|9|10|11, Q. Li¹², A. Balogh¹², A. Slaughter¹², N. Benachour¹², C. Lonardi¹², A. Ghosh¹², M. Vogel¹², N. Lendvai¹², T. Lengil¹², M. Koneru¹³, N. Patel¹³, O. Costa Filho¹³, V. Mahajan¹³, J. Martínez-López¹⁴, K. Yong¹⁵, K. Weisel¹⁶, X. Leleu¹⁷

¹ University of Bologna, Italy

² Medical College of Wisconsin, Milwaukee, USA

³ Nagoya City University, Japan

⁴ Fiona Stanley Hospital, Perth, Australia

⁵ Curtin University, Perth, Australia

⁶ Seoul National University, Korea

⁷ University of Wisconsin, Madison, USA

⁸ Centre Hospitalier Universitaire Hotel Dieu, Nantes, France

⁹ Université d’Angers, Nantes, France

¹⁰ Université de Nantes, France

¹¹ French Ministry of Health, Nantes, France

¹² Johnson & Johnson

¹³ Legend Biotech USA Inc, Somerset, USA

¹⁴ Complutense University, Madrid, Spain

¹⁵ University College London, UK

¹⁶ University Medical Center Hamburg-Eppendorf, Hamburg, Germany

¹⁷ CHU Poitiers, France

Multiple Myeloma CARTITUDE-4

P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS (386 Online Views)

R. Popat¹, K.M. Kortüm², H. Magen³, V. Mykytiv⁴, C. Liberatore⁵, E. Zamagni⁶, M.C. Da Vià⁷, E. Antonioli⁸, M. Hansson⁹, D. Santra¹⁰, D. Greer¹⁰, K. Subrt¹¹, P. Hu¹¹, E. Aeby¹¹, N. Francella¹¹, N.M. Suñe¹¹, A. Perrot¹², K. Uttervall¹³

¹ University College London Hospitals NHS Foundation Trust, UK

² University Hospital of Würzburg, Germany

³ Tel Aviv University, Israel

⁴ Cork University Hospital, Ireland

⁵ Ospedale Santo Spirito, Pescara, Italy

⁶ University of Bologna, Italy

⁷ IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

⁸ Careggi Hospital and University of Florence, Italy

⁹ Sahlgrenska University Hospital, Gothenburg, Sweden

¹⁰ Parexel International

¹¹ Johnson & Johnson

¹² Université de Toulouse, France

¹³ Karolinska University Hospital, Stockholm, Sweden

Multiple Myeloma REALiTAL Trial RRMM

P46 | CIRCULATING PLASMA CELLS AS A DYNAMIC BIOMARKER IN MULTIPLE MYELOMA PATIENTS RECEIVING CAR-T AND BISPECIFIC ANTIBODY THERAPY (237 Online Views)

I. Vigliotta¹, A. Varacalli¹, M. Talarico^1|2, M. Puppi^1|2, S. Armuzzi², B. Taurisano², I. Pistis¹, V. Solli², V. M. Vuong², E. Borsi¹, A. Vitale¹, G. Mazzocchetti^3|4, A. Croce², M. Martello¹, A. Poletti², M. Cavo², E. Manzato^1|2, E. Zamagni^1|2, C. Terragna¹

¹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy

² Department of Medical and Surgical Sciences - University of Bologna, Italy

³ FABIT-Department of Pharmacy and Biotechnology, University of Bologna, Italy

⁴ Computational and Chemical Biology, Italian Institute of Technology, CMP3VdA, Aosta, Italy

RRMM CAR-T Circulating plasma cells

P53 | NATIONWIDE EXPERIENCE WITH STANDARD OF CARE IDECABTAGENE VICLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL WORLD STUDY ON BEHALF OF THE GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO FOUNDATION (226 Online Views)

M. Puppi^1|2|3, M. Pennisi⁴, F. Monaco⁵, L. Paris⁶, S. Aquino⁷, F. Ciceri⁸, M.C. Goldaniga⁹, M. Musso¹⁰, G. Buda¹¹, M. Martino¹², P. Chiusolo¹³, F. Fazio¹⁴, R. Mina¹⁵, F. Patriarca¹⁶, M.C. Tisi¹⁷, P. Tacchetti¹, V. Marasco⁴, F. Ardizzoia^1|2|3, M. Talarico^1|2|3, K. Mancuso^1|2|3, E. Maffini¹, C. Carniti⁴, C. Terragna¹, E. Zamagni^1|2|3, F. Bonifazi¹, M. Cavo^2|3, P. Corradini⁴

¹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy

² Department of Medical and Surgical Sciences

³ (DIMEC), University of Bologna, Italy

⁴ Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, University of Milan, Italy

⁵ AOSS Antonio e Biagio e Cesare Arrigo-SC Ematologia, Alessandria, Italy

⁶ ASST Papa Giovanni XXIII, Bergamo – SC Ematologia, Italy

⁷ Ematologia e Terapie cellulari, IRCCS Ospedale Policlinico San Martino, Genova, Italy

⁸ Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy

⁹ Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

¹⁰ Dipartimento Oncologico "La Maddalena", UOC di Oncoematologia e TMO, Palermo, Italy

¹¹ Hematology Division, Pisa University Hospital, Department of Clinical and Experimental Medicine, University of Pisa, Italy

¹² Stem Cell Transplantation and Cellular Therapies Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy

¹³ Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

¹⁴ Department of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of Rome, Italy

¹⁵ AOU Città della Salute e della Scienza di Torino and the Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy

¹⁶ Clinica Ematologica ed Unità di Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy

¹⁷ Hematology Unit, San Bortolo Hospital, Vicenza, Italy

RRMM GIMEMA CAR-T

P55 | MANAGEMENT OF NEUROLOGICAL TOXICITIES OF PATIENTS TREATED WITH IMMUNOTHERAPIES FOR MULTIPLE MYELOMA: A SINGLE-CENTER REAL WORLD EXPERIENCE (277 Online Views)

¹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia L. A. Seràgnoli, Italy

² Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Italy

Multiple Myeloma Neurological Toxicities RRMM

P64 | ODISSEY: A MULTICENTER, OBSERVATIONAL STUDY OF MULTIPLE MYELOMA ITALIAN PATIENTS WHO DISCONTINUED THERAPY IN CLINICAL PRACTICE (270 Online Views)

N. Sgherza¹, E. Antonioli², E. Zamagni^3|4, C. Conticello⁵, F. Fazio⁶, S. Palmieri⁷, A. Cagnetta⁸, G. Palumbo⁹, A.G. Solimando¹⁰, R. Della Pepa¹¹, C. Germano¹², G. Palazzo¹³, C. De Risi¹⁴, A. Quinto¹⁵, G. Buda¹⁶, M. Gentile^17|18, O. Annibali¹⁹, D. De Novellis²⁰, P. Curci¹, O. Battisti¹, L. Pavan^21|22, M. Capriata⁶, G. Di Carlo¹³, G. Proietti⁶, V. Del Fabro²³, A.P. Falcone²⁴, R. Spadano²⁵, D. Derudas²⁶, G. Mele²⁷, G. Barilà²⁸, M.T. Petrucci⁶, F. Di Raimondo^5|29, F. Albano^1|30, P. Musto^1|30

¹ Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy

² Hematology Unit, Careggi University Hospital, Firenze, Italy

³ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli", Italy

⁴ Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy

⁵ Division of Hematology and Stem Cell Transplantation, Policlinico“G. Rodolico-San Marco”, Catania, Italy

⁶ Department of Translational and Precision Medicine Hematology, Sapienza University, Roma, Italy

⁷ Hematology Unit, Ospedale Cardarelli, Napoli, Italy

⁸ Hematology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy

⁹ Hematology Unit, AOU Policlinico Riuniti di Foggia, Italy

¹⁰ G. Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, University of Bari Aldo Moro, Italy

¹¹ Department of Clinical Medicine and Surgery, University Federico II, Napoli,Italy

¹² Hematology Unit,“Mons. Dimiccoli” Hospital, Barletta, Italy

¹³ Hematology Unit, “G. Moscati” Hospital, Taranto, Italy

¹⁴ Haematology and Transplant Unit, “V. Fazzi” Hospital, Lecce, Italy

¹⁵ Hematology and Cell Therapy Unit, IRCCS “G. Paolo II”, Bari, Italy

¹⁶ Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Italy

¹⁷ Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Italy

¹⁸ Department of Pharmacy, Health and Nutritional Science, University of Calabria, Italy

¹⁹ Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Biomedico di Roma, Italy

²⁰ Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy

²¹ Department of Medicine

²² (DIMED), Hematology section, Padua University School of Medicine, Italy

²³ Faculty of Medicine and Surgery “Kore”, University of Enna, Italy

²⁴ Department of Hematology and Bone Marrow Transplant, IRCSS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy

²⁵ Hematology Unit, Santo Spirito Hospital, Pescara, Italy

²⁶ Department of Hematology, Businco Hospital, Cagliari, Italy

²⁷ Hematology Unit,“A. Perrino” Hospital, Brindisi, Italy

²⁸ Hematology Unit, Ospedale San Bortolo, Vicenza, Italy

²⁹ Department of General Surgery and Medical-Surgical Specialties, Hematology Section, University of Catania, Italy

³⁰ Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, Bari, Italy

Multiple Myeloma ODISSEY study Clinical Features

B07 | PROGNOSTIC ROLE OF STANDARDIZED (18)F-FDG-PET/CT AND WB-DW-MRI IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS RECEIVING T CELL-REDIRECTING THERAPIES (399 Online Views)

¹ Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy

² IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy

³ Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy

⁴ Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy

⁵ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy

RRMM Functional Imaging T-cell Therapy

Abstract Book of the 7th European Myeloma Network Meeting, Prague, 16-18 April 2026

Advanced filters

B04 | BLOOD-BASED RISK STRATIFICATION OF MYELOMA PATIENTS USING CIRCULATING TUMOR CELLS: RESULTS FROM THE EUROPEAN CTC CONSORTIUM (364 Online Views)

P01 | CIRCULATING TUMOR CELLS IMPROVE RISK STRATIFICATION ACCORDING TO THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM AND THE IMS-IMWG CONSENSUS GENOMIC STAGING IN NDMM PATIENTS. AN ANALYSIS FROM THE EUROPEAN CTC CONSORTIUM (326 Online Views)

P16 | INTEGRATED p53 ISOFORM EXPRESSION DEFINES NOVEL PROGNOSTIC SUBGROUPS IN MULTIPLE MYELOMA (274 Online Views)

P18 | MONOCLONAL AND POLYCLONAL CIRCULATING PLASMA CELLS ARE ASSOCIATED WITH DISEASE DISSEMINATION IN MULTIPLE MYELOMA (295 Online Views)

P36 | EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER CILTACABTAGENE AUTOLEUCEL: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (393 Online Views)

P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS (386 Online Views)

P46 | CIRCULATING PLASMA CELLS AS A DYNAMIC BIOMARKER IN MULTIPLE MYELOMA PATIENTS RECEIVING CAR-T AND BISPECIFIC ANTIBODY THERAPY (237 Online Views)

P53 | NATIONWIDE EXPERIENCE WITH STANDARD OF CARE IDECABTAGENE VICLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL WORLD STUDY ON BEHALF OF THE GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO FOUNDATION (226 Online Views)

P55 | MANAGEMENT OF NEUROLOGICAL TOXICITIES OF PATIENTS TREATED WITH IMMUNOTHERAPIES FOR MULTIPLE MYELOMA: A SINGLE-CENTER REAL WORLD EXPERIENCE (277 Online Views)

P64 | ODISSEY: A MULTICENTER, OBSERVATIONAL STUDY OF MULTIPLE MYELOMA ITALIAN PATIENTS WHO DISCONTINUED THERAPY IN CLINICAL PRACTICE (270 Online Views)

B07 | PROGNOSTIC ROLE OF STANDARDIZED (18)F-FDG-PET/CT AND WB-DW-MRI IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS RECEIVING T CELL-REDIRECTING THERAPIES (399 Online Views)

Navigate

For Authors

For Reviewers

For Advertisers

Education

Privacy

More